Stocks to Watch 03-25-10

VANITY EVENTS HOLDING INCORPORATED (OTCBB: VAEV)
"Up 33.33% on Wednesday"

Detailed Quote: www.otcpicks.com/quotes/VAEV.php

Company Profile: http://www.otcpicks.com/vanity-events/vanity-events.htm

Headquartered in New York, NY, Vanity Events Holding, Inc. is a holding company with numerous expanding lines of business. Utilizing their acquired trademark of America's Cleaning Company™, Vanity has established a cleaning company offering a full range of residential and commercial cleaning services. The Company also seeks out, licenses, develops, promotes, and brings to market various innovative consumer and commercial products.

VAEV News:

March 23 - Vanity Events Holding, Inc. Announces Company Progress Report

Vanity Events Holding, Inc. (OTCBB:VAEV) ("Vanity") provided its shareholders with an overview of the Company's progress to date.

VANITY EVENTS HOLDING, INC.

Vanity Events Holding, Inc. is a holding company with two primary subsidiary companies, each with its own varied goals and objectives. The subsidiaries are Vanity Events, Inc. and America's Cleaning Company.

VANITY EVENTS, INC.

Vanity Events, Inc.'s main offices are located at 43 West 33rd Street, Suite 600 in New York City. In March 2010, Vanity Events, Inc.'s food division opened a satellite office in Queens, New York. The Company has 27 full-time, salaried employees — six in Products, five in Food, six in America's Cleaning Company — Franchising, and ten who work on corporate matters (accounting, human resources, management, operations, and information technology).

PRODUCTS DIVISION

Vanity Events, Inc. seeks out inventions, patents, and innovative products with the purpose of assisting the principles in developing and bringing those products to market. The product acquisition process is rigorous, including analyzing market research data, market trends, the ability of an individual product to significantly impact the market, and financial worthiness.

In November 2009, Vanity Events, Inc. partnered with the United Inventors Association as a corporate sponsor, giving the Company the opportunity to reach and assist inventors in a wide range of fields, while at the same time allowing the Company the opportunity to establish itself as a leader in the field of innovation.

The Company's Products Division is extremely selective in determining which products to accept. To date, the Company has reviewed hundreds of product concepts and models, of which fewer than one hundred have received non-disclosure agreements. Of those that received non-disclosures, the Company has rejected the majority after determining they were not financially worthwhile to pursue. The Company is currently in "active" status with 35 products.

FOOD DIVISION

Vanity Events, Inc. also has a Food Division which seeks out innovative food products in order to develop and bring those products to market, while also working as a distributor of food products to various institutions and restaurants.

To date, the Food Division has developed plans to sell a full line of 100% natural sorbet as well as frozen fruits grown and imported from Chile, and a full line of organic pastas — flavored and whole wheat — are planned as well. The food department has already secured a number of contracts with groceries, nursing homes, restaurants and schools, with plans to sell to other institutions including hospitals.

AMERICA'S CLEANING COMPANY — FRANCHISING DIVISION

In addition to product development, Vanity Events, Inc. also functions as the management company for the franchising plans of America's Cleaning Company. Using its licensed trademark of America's Cleaning Company™ and its recognizable logo of "Anna C. Clean", the Company plans to brand itself as the premier provider of residential and commercial cleaning on a national level, while utilizing its own proprietary, brand-name products.

In September 2009, the Company began working with a number of established firms in order to best develop the franchise model for America's Cleaning Company. The Homewood, Illinois-based iFranchise Group are the prime advisors of the Company, guiding the Company through the franchising process while helping the Company develop its franchise model. In October 2009, the Company began working with Waterstreet, a Vancouver-based technology company, to develop specialized, web-based business management software for the Company. This software will be used to estimate and schedule jobs, track inventory, run reports on revenue and costs, and will be used by every franchise, allowing the Company to track and analyze the data from franchise to franchise.

In November 2009, the Detroit-based Out of the Box Technology (formerly Technology in a Box) began developing customized Quickbooks®-based software, including a standard set of accounting guidelines to be used by each franchise. Out of the Box has also worked with Waterstreet to integrate the two technologies, allowing the Company to closely track and analyze the practices of its franchisees and to quickly assist the franchisees by promoting best practices and showing where improvements can be made.

In November 2009, the Company also began working with the Tulsa-based Intellevue, a mapping software company, to help map and establish territories for potential franchisees based on carefully examined demographic information.

AMERICA'S CLEANING COMPANY

America's Cleaning Company began as a division of Vanity Events, Inc. and became its own company in December 2009.

America's Cleaning Company is carrying out operations as a "corporate franchise prototype", designed to both determine best practices and to test the franchise management technologies in order to streamline and simplify them for potential franchisees.

The Company has performed services in the New York City boroughs of Manhattan, Queens, and Brooklyn; on Long Island; and in northern New Jersey. The number of jobs ACC has performed has steadily increased in five of six months, beginning with 10 jobs carried out in the month of September, growing to 109 jobs carried out in the month of March.

America's Cleaning Company has four full-time salaried employees, and utilizes part-time workers as needed to carry out its services.

In March 2010, the Company began a partnership with America Works, a nationally recognized agency which specializes in intensive, personalized employment services. America's Cleaning Company is able to hire pre-screened, quality employees directly through America Works.

CYTTA CORPORATION (OTCBB: CYCA)
"Up 157.89% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/CYCA.php

Cytta Corp. does not have significant operations. The company holds a license to manufacture, sell, distribute, operate, sub-license, and market various technology-based Internet access, and computing products and services, which consist of Internet access devices, software and hardware, and various medical peripherals designed and adapted to provide remote non-diagnostic monitoring of home based and remote patients. It plans to develop these Internet access devices. Cytta Corp. was founded in 2006 and is based in Mill Valley, California.

CYCA News:

March 19 - Cytta Appoints Exceptional Vice President and Director to Coordinate Medical Project

Cytta Corp. (OTCBB: CYCA) announced that Mr. Karl Harz B.Sc. (Marketing), MBA has been appointed Vice President Business Development and has been elected to the Board of Directors to work with Mr. Stephen Spalding the CEO.

Mr. Harz has many years of experience in the identification, negotiation and acquisition of a myriad of projects ranging from technology, real estate and most recently mining and resource. Mr. Harz with his wife Marilyn K. Harz RN, Ph.D. continue to work together in the development of medical products to better manage the healthcare needs of people with chronic conditions in preparation for healthcare reform.

The crucial involvement of Mr. Harz in Cytta allows us to further our mission to discover, acquire and develop technologically advanced products. Mr. Harz's involvement is related to our discussions with a major partner wishing to assist in the implementation of the home based medical testing systems previously acquired by the Company and currently described as the 'Advanced Medical Project.'

Given the interest currently being displayed in the tremendous savings this technology can deliver to the US Healthcare industry by both industry and government alike, and the Company's Officers knowledge of the field, the Company will hereafter be focusing its ongoing efforts upon implementing these technologies.

The Company also wishes to announce, that it will through the license agreement acquired from Lifespan Inc. continue to focus upon becoming the leading provider of Internet based home medical diagnostic and testing products. Additionally, the Company wishes to announce that Dr. Albert Cook BA, MD will not be joining the Board of Directors or serve as Medical Director as previously announced. Additionally, the Company will be ceasing all negotiations regarding the ScreenMD project.

The primary benefits of Cytta's medical model are clinical, resulting in superior patient outcomes, psychosocial, resulting in better patient satisfaction, and economic, resulting in significantly lower costs. The Advanced Medical system is focused upon connecting leading edge home based medical diagnostic and testing equipment securely through any wireless device to the client's Electronic Medical Record portal.

The medical peripherals and devices which the Company seeks to integrate are designed to simplify the collocation of medical data in the home and securely deliver the core medical data to web based medical portals. The system envisaged by the Company allows for easy access, review, and storage by the user and/or their designated medical professionals from anywhere in the world.

The Company seeks to develop its technological expertise, joint venture relationships and strategic alliances to positioned itself to become a leading integrator of Internet based medical diagnostic and testing products utilizing screen based wireless access devices to reach the ever-growing market segment requiring access to "instant medical testing" and "electronic diagnosis" products. Company management envisions explosive growth as the US moves towards more universal access to home based advanced medical evaluation systems and the current Health Care changes being proposed by Congress resolve into functional improvements.

Mr. Harz has maintained a California Real Estate Broker's License and has had a Series 22 and 63 licenses, a Life and Disability license and Variable Annuity License. Mr. Harz graduated from Fairleigh Dickinson University in Teaneck, N.J., with a Bachelor of Science in Marketing and a Masters in Business Administration in Management. While attending Farleigh on a full track and field scholarship, Mr. Harz won a National AAU title competing in the All-Arounds which awarded him recognition as being on the first team of the All American Men's Track and Field Outdoor Team.

Mr. Harz has previously been instrumental in the development and management of a major corporation, Transitional Housing Inc. (THI). THI was awarded a contract through the US Department of Justice for the housing of undocumented persons. This was a 300 bed contract requiring the development of a medical clinic for the healthcare needs, 24 hour security, transportation and legal assistance. Other contracts grossing over a billion dollars were awarded with the assistance of Mr. Harz for the housing and welfare of these groups of individuals across the United States.

MED GEN INCORPORATED (OTCBB: MDIN)
"Up 125.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/MDIN.php

Med Gen Inc., in business since 1996, manufactures and markets specialty products using its proprietary delivery system, Spray’s the Way (“STW”). It is best known for producing the world’s first patented liquid spray snoring relief formula, Snorenz®. Since its existence, Med Gen has continued to develop its STW technology, introducing Good Nights Sleep®, the UnDiet® system and GOOD NIGHTS SLEEP® Sleep Strips into its family of brands. FabULust™, the company’s newest product, a female sexual stimulant, has been launched in test markets throughout the country. While STW technology is mainly used, the company also produces other products that deal with common health issues using other delivery systems. The company markets its products to distributors, direct sales via the company web site and direct to consumer television, radio and print advertising. The company also distributes its brands internationally under various private labels or existing names. The Company also offers specialty financial and investment services through its Financial Services division, to small emerging public companies.

MDIN News:

March 24 - Med Gen Launches Web Based Business Broker Training System to the Public

Med Gen Inc. (OTC: MDIN) announced that its wholly owned subsidiary, NorthStar Business and Property Brokers, Inc. has launched Bizbrokerschool.com, an online interactive training program that offers subscribers the opportunity to learn all aspects of business brokering, enabling them to launch a career as a business broker.

The website contains the latest version of the company's extensive training guide, including multiple choice quizzes and a final examination to ensure the student retains the information necessary to become a successful business broker. The company also offers subscribers who pass the exam a contract with NorthStar as an independently contracted business broker.

"This is really exciting! Now we can begin expanding our scope nationwide, giving individuals an opportunity to take advantage of this lucrative market by providing them with the tools and education they need to succeed," said Raymond Barton, Med Gen's CEO. Mr. Barton added that "besides helping individuals create their own future we are also providing an invaluable service to business owners across the country. In many situations business brokers are essentially rescuing certain owners from losing their business entirely."

According to the company's CFO Timothy Schmidt, the company can earn as much as 12% of the total sales price of a business and pays an 80% commission to NorthStar brokers bringing the business and/or buyer to the table. Mr. Schmidt adds that with over 17 million businesses in the U.S. and approximately 3.4 million businesses being sold each year, business brokering is quickly becoming a significant career opportunity as there are only 4,000 business brokers currently operating across the country. The company strongly recommends that future business brokers check with their local and state governments regarding licensure as it varies from state to state. Approximately sixteen states now require a license to broker businesses. Bizbrokerschool.com does not make any representation that it conforms to any state licensing requirements and it is the student's responsibility to verify their own applicable rules, laws and regulations.

Med Gen Inc. went public in 1997 and distributed health related products. Business wound down in 2008 but was recently revived earlier this year through its wholly owned subsidiary, NorthStar Business and Property Brokers, Inc., a private company engaged primarily in business brokering.

CHROMOCURE INCORPORATED (OTC: KKUR)
"Up 50.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/KKUR.php

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide. The Company's technology and cancer expertise also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

KKUR News:

March 18 - ChromoCure Heralds Publication of 'Polyploidization and Cancer' as Paradigm Shift in Cancer Diagnosis and Therapy: Company Expects Increased Demand for Its ChromoSomal Scanning Technology

ChromoCure, Inc. (OTC: KKUR) heralds the March 15, 2010 publication of "Polyploidization and Cancer." This publication is viewed as a major turning point and paradigm shift in the diagnosis, therapy and cure of cancer. The Company views this as significant support of its long held theory of cancer and its Chromosomal Scanner detection technology. Published as part of Advances in Experimental Medicine and Biology Series: Vol. 676 (ISBN: 978-1-4419-6198-3) and edited by Randy Y.C. Poon, this book brings together leaders of the field to overview subjects relating to Polyploidization, aneuploidy and cancer.

This authoritative collection of research further corroborates recent studies by Mayo Clinic and others that have conclusively and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure designs its technology around the chromosomal theory of cancer.

The Company's proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to other detection approaches presently employed by pathologists, including biomarker detection, in every measurable way. ChromoCure's systems measure aneuploidy as the sole means of detecting cancer presence and measuring cancer progression. The system has a 100% effective accuracy rate, as verified in the recently published collaborative clinical testing with a major cancer clinic.

The company's technology and related research opens the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. Given the significant change in scientific views currently underway, the company has aligned itself to focus its leadership status to therapeutics research. These new initiatives add to the Company's existing scanner technologies which include proprietary designs, processes, and algorithms centered on chromosomal imbalance. The Company believes its technologies provide the foundation for significant advantages in delivering important results in diagnosis, therapy and cure.

The Company invites industry and scientific collaboration through its "Project Boveri: Find the Cure" initiative.

GENTIUM S.P.A. (NASDAQ: GENT)
"Up 77.47% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/GENT.php

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.

GENT News:

March 23 - Gentium Announces Defibrotide Results Highlighted at Opening Session and Symposium at EBMT Annual Meeting

* Utility in prevention of hepatic veno-occlusive disease and acute graft vs host disease in high risk children
* New insights into biological mechanism of action
* Subject of satellite symposium with key opinion leaders

Gentium S.p.A. (Nasdaq: GENT) announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation (EBMT) 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.

This Phase II/III, randomized, controlled study evaluated the prophylactic use of Defibrotide in pediatric stem cell transplant (SCT) patients at high risk for veno-occulsive disease (VOD). In the intent to treat analysis (ITT), which included 356 patients (180 patients in the prophylaxis arm and 176 in the control arm), Defibrotide demonstrated a 40% reduction in the incidence of VOD within 30 days after SCT, the primary endpoint of the study. VOD incidence was 20% in the control arm and 12% in the prophylaxis arm (p=0.0488 Competing Risk; p=0.0507 Kaplan-Meier). In the per-protocol analysis, the VOD incidence was 20% in the control arm and 11% in the prophylaxis arm (p=0.0225 Competing Risk; p=0.0234 Kaplan-Meier). A p-value equal to or less than 0.05 is needed to achieve statistical significance.

In addition, a pre-specified analysis showed that the incidence and severity of acute graft versus host disease (GvHD) by day 100 in allogeneic SCT recipients was significantly reduced from 63% for the control arm to 45% for the prophylaxis arm (p=0.0046 for incidence of GvHD and p=0.0034 for severity). Renal failure was reduced from 6% in the control group to 1% in the Defibrotide group (p=0.0169). With regard to safety, Defibrotide was well tolerated and no difference in adverse events was observed between the two study arms.

"The results from the study demonstrated that Defibrotide reduced the incidence of VOD in high risk pediatric patients," stated Dr. Selim Corbacioglu. "SCT patients who develop VOD, regardless of its severity and despite prompt treatment, have a mortality rate four times greater than patients without VOD. We are also very enthusiastic that Defibrotide has the potential to reduce the incidence and severity of acute GvHD, a life threatening complication, which is frequent in SCT and has limited treatment options. We believe that Defibrotide could have a future role for the prevention of GvHD."

"The Defibrotide VOD prevention study was the largest study performed in the pediatric SCT setting and its results have been included in the press conference of the EBMT," said Professor Dietger Niederwieser of University of Leipzig, Chairman of the opening session, President of the EBMT, and newly elected president of the Worldwide Network for Blood & Marrow Transplantation (WBMT). "The results of this study, which demonstrate a reduction in VOD as well as the potential beneficial effects on GvHD and renal failure, are consistent with the effects of endothelial protection and confirm the potential of Defibrotide in preventing transplant related toxicities."

"We are very encouraged by the recognition of this study by the leaders of the European hematology community," said Dr. Massimo Iacobelli, Scientific Director of Gentium. "We are fully engaged in preparing the regulatory submissions for the prevention and treatment of VOD."

Defibrotide's biological activity and mechanism of action were highlighted in a separate poster-presentation, "Defibrotide protects human microvascular endothelial cells from fludarabine-mediated pro-inflammatory and pro-apoptotic signals: a microarray (Affimetrix) analysis." This study provides new biological insights on how Defibrotide might protect endothelial cells against chemotherapy-induced activation and cell death, without affecting the antileukemic effect of fludarabine and without affecting normal endothelium.

The satellite symposium "Defibrotide for the Prevention and Treatment of Hepatic VOD following stem cell transplant," was very well attended, featuring presentations by key opinion leaders Dr. Ernst Holler (University of Regensburg); Dr. Selim Corbacioglu (University of Regensburg); Dr. Paul Richardson (Dana Farber Cancer Institute, Boston, US), and Dr. Enric Carreras (University of Barcelona). The symposium was chaired by Dr. Rob Soiffer (Dana Farber Cancer Institute, Boston, US).

ABOUT THE EBMT AND THE VAN BEKKUM AWARD

The European Group for Blood and Marrow Transplantation (EBMT) is a European non-profit organization that was established in 1974 to allow scientists and physicians involved in clinical bone marrow transplantation to share their experience and develop cooperative studies. Representing 527 transplant centers across 57 countries in and outside of Europe, the EBMT promotes all activity aiming to improve stem cell transplantation or cellular therapy.

The Van Bekkum award is named for Dr. Dirk Van Bekkum, who is internationally recognized for his work in bone marrow transplantation; among other achievements, his laboratory was the first to identify what is now known to be graft-versus-host disease.

ABOUT THE PHASE II/III EUROPEAN PEDIATRIC PREVENTION TRIAL

The EBMT phase II/III European pediatric prevention trial was a prospective, multi-center, open label, randomized clinical trial to evaluate the prophylactic use of Defibrotide in patients under 18 years of age who were undergoing stem cell transplantation (SCT) and were at high risk for developing hepatic Veno-Occlusive Disease (VOD). Patients randomized in the prophylaxis arm received 25 mg/kg/day of Defibrotide in four divided doses beginning at the time of conditioning and until 30 days post transplant. Patients randomized to the control arm received no VOD prophylactic therapy. Patients were permitted to receive Defibrotide as therapy if they developed VOD. The primary endpoint of the study was development of VOD within 30 days post SCT, based on the modified Seattle criteria. A blinded independent review committee of three expert hematologists confirmed the diagnosis of VOD.

ABOUT VOD

Veno-occlusive disease is a potentially life-threatening condition, which typically occurs as an important complication of stem cell transplantation. Certain high-dose conditioning regimens used as part of SCT can damage the lining cells of hepatic blood vessels and so result in VOD, a blockage of the small veins of the liver that leads to liver failure and can result in significant dysfunction in other organs such as the kidneys and lungs (so-called severe VOD). SCT is a frequently used treatment modality following high-dose chemotherapy and radiation therapy for hematologic cancers and other conditions in both adults and children. There is currently no approved agent for the treatment or prevention of VOD in the US or the EU.

ABOUT GVHD

Graft-versus-host disease (GVHD) is a complication that occurs frequently after allogeneic stem cell transplantation, where with to the blood forming cells a completely new immune system is transplanted from the donor. The differences between the donor and recipient often cause T cells (a subtype of white blood cells) from the donor to recognize the recipient's body tissues as foreign. When this happens, the newly transplanted immune system attacks the transplant recipient's body. Risk of GvHD increases with the degree of mismatch between donor and recipient.

CLEAN COAL TECHNOLOGIES (OTC: CCTC)
"Up 27.29% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/CCTC.php

CCTI, which began operations on September 1, 2007, was formed through the acquisition of Clean Coal Systems, Inc. (CCSI) and a pink sheet shell company that facilitated CCTI's listing on the OTC exchange in early October, 2007 under the symbol "CCTC." CCTI's technology will be marketed through a variety of contractual relationships, including joint ventures, licensing agreements, and build/operate/transfer relationships. CCTI's technology is far superior to coal scrubbing and costs 60-70% less, because it removes pollutants and contaminants that scrubbing does not address. It is truly the "Pollution Solution." The technology allows raw, low-grade coal to be transformed via our multistage patented processes into high grade, clean burning, coal, on an industrial scale.

CCTC News:

March 24 - Clean Coal Technologies Inc. Announces That Major Joint Venture in China is on Track for April

Clean Coal Technologies, Inc. (OTC: CCTC) will sign a joint venture agreement in China in early April, with similar agreements in India and the U.S. not far behind.

“We expect to sign our first joint venture agreement in China in early April,” said Doug Hague, President & CEO of the innovative company. “We’re still on track to expand our penetration into the China market.

“It is our first technical license agreement in China, and it denotes the continued acceptance of our technology,” he continued.

With CCTI’s new technology, coal becomes a cost-effective, efficient and extremely clean-burning fuel that could potentially reduce our dependency upon oil.

Hague added that Clean Coal Technologies’ India project is on track, with revenues expected in the near future.

As far as the U.S. market, Hague said that “The recent appointment of Randall Business Systems means we’re on track to sign our first technical license agreement before the end of the year.”

The company will be filing its 10K with the SEC soon. “All the fundamentals will illustrate that the company is sound and following our previously stated objectives,” Hague said.